Novartis Kisqali® 5-year NATALEE data demonstrate 28% reduction in risk of recurrence in the broadest early breast cancer patient population

Novartis Kisqali® 5-year NATALEE data demonstrate 28% reduction in risk of recurrence in the broadest early breast cancer patient population
arcticnovartis

  • After 5 years, Kisqali® plus endocrine therapy consistently shows significant and clinically meaningful benefit in invasive disease-free survival1
  • Kisqali remains the only CDK4/6 inhibitor demonstrating consistent and clinically meaningful benefit across the broadest population of HR+/HER2- early breast cancer (EBC) patients, including those with node-negative disease1  
/by
Novartis Scemblix® receives positive CHMP opinion for the treatment of adults with newly diagnosed CML

Novartis Scemblix® receives positive CHMP opinion for the treatment of adults with newly diagnosed CML
arcticnovartis

  • If approved, Scemblix will be indicated for adults with chronic myeloid leukemia (CML), both newly diagnosed and previously treated, expanding access to four times as many patients in Europe
  • Scemblix is the only CML treatment with a superior efficacy and favorable safety and tolerability profile versus available first-line treatments1,2
/by